Author "scarlettzou" Page

Author Nick: scarlettzou

Author Articles List:

Sort by:

Development History of ADC Drugs

Antibody-drug conjugate (ADC) consists of linker, payload, and monoclonal antibody (mAb). It combines the advantages of high specific targeting ability and strong killing effect to achieve accurate and efficient killing of cancer cells, which has become one of the hot spots in the research and development of anticancer drugs. Since the first ADC drug Mylotarg […]

ADC Targets And Representative Drugs For Non-Small Cell Lung Cancer (NSCLC)

Technological advances have re-established ADC as a viable treatment strategy for advanced solid tumors. ADCs targeting several tumor targets have shown great potential in the treatment of refractory NSCLC, including HER2, HER3, TROP2, CEACAM5, and MET. On August 11, 2022, the FDA accelerated approval of Enhertu (trastuzumab deruxtecan, T‑DXd), a HER2 ADC drug jointly developed […]

The Path To The Development of COVID-19 mRNA Vaccines

Since the first successful application of messenger ribonucleic acid (mRNA) as a vaccine agent in clinical studies, many advances have been made in the field of mRNA therapeutic technology after nearly 30 years of development. Vaccines are essential tools for the prevention, control and/or eradication of infectious diseases and are an essential part of global […]

The Future of Treatment For Type 2 Diabetes

Although the treatment of type 2 diabetes (T2DM) has made impressive progress in the past few decades, researchers are constantly searching for new treatments. How to better control blood glucose and reduce diabetes-related complications has become a hot topic in the field of T2DM research.   Previously, The Lancet Diabetes Endocrinology published an in-depth review […]

9 Classes of Drug Conjugates: Characteristics, Development Progress And Future Development Trend

In the field of targeted delivery of drug conjugates, the concept of the magic bullet was proposed more than a hundred years ago. Magic bullet drugs can specifically identify and kill cancer cells without harming normal cells. With the continuous progress of protein genetic engineering, chemical conjugation and other technologies, the field of targeted delivery […]

Potential Applications of mRNA Technology: Ophthalmology Could Be A Breakthrough

Since the COVID-19 epidemic, Pfizer and Moderna have used mRNA technology in a vaccine to help humans fight COVID-19. While mRNA technology is new to the public, the research has been around since the early 1990s. What is an mRNA vaccine? An mRNA vaccine is a vaccine that uses a molecular copy of messenger RNA […]

A Review of Therapies For Alzheimer’s Disease

Alzheimer’s disease (AD) is a progressive, irreversible neurodegenerative disease clinically manifested by cognitive impairment, behavioral abnormalities, and social deficits. It is predicted that by 2050, the number of people 65 and older with dementia in the United States could reach 13.8 million. In China, more than 15.07 million elderly people aged 60 or over suffer from […]

New Technology of PROTACs

Most of the drugs currently in clinical use are based on small molecules and use the “occupancy-driven” mode of action to inhibit the function of proteins and play a role in the treatment of diseases. Different from traditional small molecule inhibitors and antagonists, protein degradation technology has developed rapidly in recent years because of its […]

Molecular Glue And Its Application In New Drug Development

In recent years, targeted protein degraders have entered the mainstream of drug development at a very rapid rate. Thalidomide and its derivatives for the treatment of multiple myeloma and other conditions have demonstrated the potential of protein degraders, while ARV-471, an estrogen receptor degrader based on the drug development of thalidomide, is targeted at the […]

A Combination of Ramucirumab Plus Pembrolizumab Lengthened Survival For Some Lung Cancer Patients

A study conducted under the Lung Cancer Master Protocol (Lung-MAP) found that when treated with a combination of ramuzumab (Cyramza) and Keytruda,  Patients with advanced NSCLC whose cancer progressed during prior immunotherapy lived significantly longer than when treated with one of the current standard therapies for this cancer. The hazard ratio (80% confidence interval) for overall survival […]